Cardiovascular disease
Conditions
Interventions
Combination and separate medication groups:None
Use of GLP-1RA:None
Use of SGLT2i:None
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Patients receive prescriptions for GLP-1 receptor agonists (dulagtopide, exenatide, liraglutide, semegglutide) and/or SGLT-2 inhibitors (caglopiliflozin, dapaglopiliflozin, engaliflozin) between January 1, 2022 and May 30, 2025. 2. The patient is 18 years old or older. 3. The patient has at least half a year medical history in the HIS system. 4. The patient meets the definition of cardiorenal metabolic syndrome and distinguishes the disease stages of different patients. 5. Informed consent form for biological sample donation has been signed, agreeing to donate its samples and data for use in all medical research
Exclusion criteria
Exclusion criteria: 1. Patients with previous diagnosis of type 1 diabetes; 2. Patients with contraindications to research drug, such as end-stage renal disease and multiple endocrine tumor syndrome; 3. Patients lacking important clinical data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main cardiovascular events;renal events; | — |
Secondary
| Measure | Time frame |
|---|---|
| All-Cause Mortality;Hospitalization rate for heart failure;eGFR change rate;Changes in urinary protein/creatinine ratio;HbA1c compliance rate; | — |
Countries
China
Contacts
Public ContactYanrong Ye
Zhongshan Hospital, Fudan University
Outcome results
None listed